Appraisal specific projects

These are projects commissioned by NICE in relation to the appraisal of specific technologies under the Multiple Technology Appraisal (MTA) and Single Technology Appraisal (STA) programmes.


Alzheimer’s disease

TA111 Alzheimer’s disease – donepezil, rivastigmine, galantamine and memantine

Age-related macular degeneration

TA155 Age-related macular degeneration – ranibizumab and pegaptanib

Ankylosing spondylitis

TA143 Ankylosing spondylitis – adalimumab, etanercept and infliximab

Breast cancer

ID20 Breast cancer – lapatinib

TA496 Breast cancer – ribociclib

Colorectal cancer

TA176 Colorectal cancer – cetuximab

Crohn's disease

TA187 Crohn's disease – adalimumab and infliximab


TA288 Diabetes – dapagliflozin

TA203 Diabetes – liraglutide

Lung Cancer

TA162 Lung cancer – erlotinib


ID416 Lupus – belimumab

Macular oedema

TA274 Macular oedema – bevacizumab

Myelodysplastic syndromes

TA128 Myelodysplastic syndromes – azacitidine


TA160 / TA161 Osteoporosis – alendronate, etidronate, risedronate, raloxifene, teriparatide and strontium ranelate

Prostate cancer

ID590 Prostate cancer – degarelix

Renal cell carcinoma

TA178 Renal cell carcinoma – bevacizumab, sorafenib, sunitinib and temsirolimus

Rheumatoid arthritis

TA130 Rheumatoid arthritis – adalimumab, etanercept and infliximab

Rheumatoid arthritis – adalimumab, etanercept and infliximab (sequential use)

ID537 Rheumatoid arthritis – adalimumab, etanercept, inflizimab, certolizumab pegol, golimumab, abatacept and tocilizumab

TA247 Rheumatoid arthritis – tocilizumab

A world top-100 university

We're a world top-100 university renowned for the excellence, impact and distinctiveness of our research-led learning and teaching.